| MOLECULES OF THE MILLENNIUM |
|
| Year : 2014 | Volume
: 5
| Issue : 3 | Page : 222-224 |
|
|
Delamanid: A new armor in combating drug-resistant tuberculosis
Alphienes Stanley Xavier, Mageshwaran Lakshmanan
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
Correspondence Address:
Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605 006
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0976-500X.136121
|
|
|
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
